Literature DB >> 10999845

Heterogeneity of nuclear lamin A mutations in Dunnigan-type familial partial lipodystrophy.

R A Hegele1, H Cao, C M Anderson, I M Hramiak.   

Abstract

We previously identified a novel mutation, namely LMNA R482Q, that was found to underlie Dunnigan-type partial lipodystrophy (FPLD) and diabetes in an extended Canadian kindred. We have since sequenced LMNA in five additional Canadian FPLD probands and herein report three new rare missense mutations in LMNA: V440M, R482W, and R584H. One severely affected subject was a compound heterozygote for both V440M and R482Q. The findings indicated that 1) a spectrum of LMNA mutations underlies FPLD; 2) aberrant lamin A, and not lamin C, is likely to underlie FPLD, as R584H occurs within LMNA sequence that is specific for lamin A; 3) the V440M mutation may not cause lipodystrophy on its own; 4) compound heterozygosity for V440M and R482Q is associated with a relatively more severe FPLD phenotype, but not with complete lipodystrophy; and 5) variation in the severity of the phenotype might be related to environmental factors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10999845     DOI: 10.1210/jcem.85.9.6822

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

Review 1.  Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.

Authors:  Alan Chait; Ira Goldberg
Journal:  Curr Diab Rep       Date:  2017-09-27       Impact factor: 4.810

2.  Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants.

Authors:  Hilal Sekizkardes; Elaine Cochran; Noemi Malandrino; Abhimanyu Garg; Rebecca J Brown
Journal:  J Clin Endocrinol Metab       Date:  2019-08-01       Impact factor: 5.958

Review 3.  Insulin resistance in human partial lipodystrophy.

Authors:  R A Hegele
Journal:  Curr Atheroscler Rep       Date:  2000-09       Impact factor: 5.113

4.  LMNA mutations, skeletal muscle lipid metabolism, and insulin resistance.

Authors:  Michael Boschmann; Stefan Engeli; Cedric Moro; Angelika Luedtke; Frauke Adams; Kerstin Gorzelniak; Gabriele Rahn; Anja Mähler; Kerstin Dobberstein; Antje Krüger; Saskia Schmidt; Simone Spuler; Friedrich C Luft; Steven R Smith; Hartmut H-J Schmidt; Jens Jordan
Journal:  J Clin Endocrinol Metab       Date:  2010-02-03       Impact factor: 5.958

5.  The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation.

Authors:  Kari M Wojtanik; Keith Edgemon; Srikant Viswanadha; Brigette Lindsey; Martin Haluzik; Weiping Chen; George Poy; Marc Reitman; Constantine Londos
Journal:  J Lipid Res       Date:  2009-02-05       Impact factor: 5.922

6.  Familial partial lipodystrophy, Dunnigan variety - challenges for patient care during pregnancy: a case report.

Authors:  Sandra Patrícia Mota Belo; Ângela Celeste Magalhães; Paula Freitas; Davide Maurício Carvalho
Journal:  BMC Res Notes       Date:  2015-04-11

7.  Reduced expression of lamin A/C correlates with poor histological differentiation and prognosis in primary gastric carcinoma.

Authors:  Zhengrong Wu; Lirong Wu; Desheng Weng; Dazhi Xu; Jian Geng; Fei Zhao
Journal:  J Exp Clin Cancer Res       Date:  2009-01-15

8.  Familial partial lipodystrophy associated with compound heterozygosity for novel mutations in the LMNA gene.

Authors:  D B Savage; M A Soos; A Powlson; S O'Rahilly; I McFarlane; D J Halsall; I Barroso; E L Thomas; J D Bell; I Scobie; P E Belchetz; W F Kelly; A J Schafer
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

9.  Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia.

Authors:  Henian Cao; Lindsay Alston; Jennifer Ruschman; Robert A Hegele
Journal:  Lipids Health Dis       Date:  2008-01-31       Impact factor: 3.876

Review 10.  Lipodystrophic laminopathies: Diagnostic clues.

Authors:  Cristina Guillín-Amarelle; Antía Fernández-Pombo; Sofía Sánchez-Iglesias; David Araújo-Vilar
Journal:  Nucleus       Date:  2018-01-01       Impact factor: 4.197

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.